Overview
- An MHLW expert committee on Feb. 19 endorsed early, conditional manufacturing and marketing approval for Reheart for severe heart failure and Amshepri for Parkinson's disease.
- The health minister said formal approval could be issued as early as early March, positioning the therapies for initial use later in 2026 pending operational preparations.
- Reheart, developed by Osaka University spinout Quolips, is a heart muscle sheet for advanced ischemic heart failure; an eight-patient trial reported symptom improvement in all participants with no tumor formation.
- Amshepri, submitted by Sumitomo Pharma, transplants iPS-derived dopaminergic progenitors; in a Kyoto University trial of six patients, four showed motor or symptom improvement without signs of tumorigenesis.
- Both products fall under Japan's conditional, time-limited pathway requiring additional safety and efficacy data over up to seven years, while pricing, insurance coverage and manufacturing scale-up are readied.